Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the safety run in Phase I portion of this study is to confirm the recommended
Phase II dose of ipilimumab and nivolumab among participants treated with combined thoracic
radiation therapy (30 Gy in 10 fractions) and nivolumab/ipilimumab following standard
treatment with 4-6 cycles of platinum-based chemotherapy.
The purpose of the Phase II portion of this study is to estimate the 6-month Progression Free
Survival (PFS) rate among participants treated with ipilimumab and nivolumab with thoracic
radiation therapy (30 Gy in 10 fractions) after standard treatment with 4 to 6 cycles of
platinum based chemotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute